Notice NOT-AG-23-016 from the NIH Guide for Grants and Contracts

Notice NOT-AI-23-036 from the NIH Guide for Grants and Contracts

Notice NOT-GM-23-018 from the NIH Guide for Grants and Contracts

Notice NOT-DK-23-016 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-23-028 from the NIH Guide for Grants and Contracts. The overall goal of this UG3/UH3 Exploratory/Developmental phased initiative is to support the discovery and development of novel natural products that are safe, nontoxic, and efficacious for cancer interception and prevention. 1. Purpose of UG3: Select clinically relevant targets and develop and validate assays for bioactivity as well as toxicity screening 2. Purpose of UH3 phase: Screening libraries, structure elucidation, full-scale characterization, efficacy testing, and development of the screened agents.

Notice NOT-CA-23-053 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-23-139 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports translational exploratory/developmental research that directly advances the discovery of novel treatment strategies, i.e., medical countermeasures (MCMs), that address serious morbidity and mortality after acute exposure to highly toxic chemical threats. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage, or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pesticides, and ultra-potent synthetic (UPS) opioids. This FOA supports translational research that includes, but is not limited to, preliminary efficacy and/or early preclinical development studies towards discovery and validation of novel molecular entities or biologics as candidate MCMs. In addition to novel agents, new treatment strategies may involve repurposing already FDA-approved products or combinations of interventions based on established mechanisms of action. Projects supported by this FOA are expected to generate preliminary data that would facilitate the development of competitive applications for more extensive support from the NIH CounterACT Cooperative Agreement program and/or other related initiatives.

Notice NOT-AT-24-002 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-RM-23-008 from the NIH Guide for Grants and Contracts. This limited competition FOA invites applications for a Bioinformatics Center to serve as part of the Molecular Transducers of Physical Activity Consortium (MoTrPAC; http://commonfund.nih.gov/MolecularTransducers). The overall goals of the Bioinformatics Center are to provide a database and associated tools for storage and integration of clinical physiological and metabolic data along with multiple types of chemical analysis data derived through metabolomics, proteomics, genomics, transcriptomics, or similar technologies. The Bioinformatics Center coordinates implementation of data and ontology-based metadata standards, provides tools for analysis and visualization of data, provides rapid access to accumulated data and tools through the use of cloud-based computing, and leads data analysis of the diverse datasets submitted by other MoTrPAC elements.

Funding Opportunity RFA-RM-23-009 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to invite applications for Chemical Analysis Sites to serve as part of the Molecular Transducers of Physical Activity Consortium (MoTrPAC; http://commonfund.nih.gov/MolecularTransducers). This is a limited competition FOA and open only to the previously funded grantees of MoTrPAC Chemical Analysis sites through RFA-RM-15-010 and RFA-RM-15-011. Awards made through this FOA will support participation of grantees in the MoTrPAC consortium activities and the continuation of the analysis of tissues collected by the MoTrPAC consortium. Awardees will conduct omics analysis of tissues collected from human participants undergoing a physical activity intervention, generate well curated datasets, contribute that data to a public consortium database, and participate in the data analysis to generate molecular fingerprints of candidate transducers of physical activity.

Funding Opportunity RFA-RM-23-011 from the NIH Guide for Grants and Contracts. This Limited Competition Funding Opportunity Announcement (NOFO) invites applications for a Consortium Coordinating Center (CCC) to serve as part of the Molecular Transducers of Physical Activity Consortia (MoTrPAC). The goals of the CCC are to provide overall coordination of the Consortium, to monitor study protocol implementation, to coordinate the collection and distribution of data and biological samples from MoTrPAC studies, and to contribute to the creation of a resource for future researchers. Only current MoTrPAC clinical coordinating center awardees are eligible to apply. These will be collaborative cooperative agreements and applicants are expected to use the uniform IRB approved MoTrPAC protocol and have research approaches in accordance with DSMB guidance for analysis of clinical trial data.

Funding Opportunity RFA-RM-23-010 from the NIH Guide for Grants and Contracts. This Limited Competition Funding Opportunity Announcement (NOFO) invites applications to complete recruitment and follow-up for the Molecular Transducers of Physical Activity Consortia (MoTrPAC) clinical studies, including finishing mechanistic randomized controlled trials of sedentary adults and children and observational studies of highly active adults and children. Only current MoTrPAC clinical center awardees are eligible to apply. These will be collaborative cooperative agreements and applicants are expected to use the uniform IRB approved protocol and have research approaches in accordance with DSMB guidance for analysis of clinical trial data.

Funding Opportunity RFA-ES-23-008 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) supports Phase I (R43), Phase II (R44), Direct to Phase II (R44), and Fast Track (R44) Small Business Innovative Research (SBIR) grant applications from small businesses concerns (SBCs) to develop resources, new methods, and approaches that can be applied in testing strategies to help understand the role of environmental chemicals in the etiology of the neurodevelopmental disorders. There is a need for novel and innovative approaches including New Approach Methodologies (NAMs) that can provide effective ways to address current challenges and gaps in the assessment of Developmental Neurotoxicity (DNT). These screening systems or technologies, when fully developed and validated with appropriate throughput and controls, are expected to provide cost-effective, quicker and/or comprehensive results to understand the underlying role of environmental chemicals in the DNT.

Funding Opportunity RFA-MH-23-140 from the NIH Guide for Grants and Contracts. This FOA seeks research applications for effectiveness and implementation science on the post-acute (long-term or chronic) management of mental health conditions. This funding opportunity aims to advance the development of novel and innovative implementation research to improve the availability and accessibility of post-acute services in low- and middle-income countries (LMICs) and low resource settings. As such, all successful applications are expected to provide approaches to obtain new information concerning the different health system arrangements and using this information to identify modifiable a restrictions in the supply of these services and potential policy interventions to alter the status quo.

Funding Opportunity PAR-23-138 from the NIH Guide for Grants and Contracts. The Instrumentation Grant Program for Resource-Limited Institutions supports the purchase of state-of-the-art scientific instruments to enhance the research and educational missions of resource-limited institutions. Requested instruments may support biomedical research and education in basic, translational, biomedically-related behavioral or clinical fields.

Notice NOT-CA-23-051 from the NIH Guide for Grants and Contracts

Notice NOT-GM-23-024 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-265 from the NIH Guide for Grants and Contracts. Reissue of PAR-17-096. The Jointly Sponsored NIH Predoctoral Training Program in the Neurosciences (JSPTPN) is an institutional program that supports broad and fundamental research training in the neurosciences. In addition to a broad education in the neurosciences, a key component will be a curriculum that provides a strong foundation in experimental design, statistical methodology and quantitative reasoning. JSPTPN programs are intended to be 2 years in duration and students may only be appointed to this training grant during the first 2 years of their graduate research training. The primary objective is to prepare students to be outstanding scientists equipped to pursue careers in neuroscience.

Funding Opportunity PAR-23-269 from the NIH Guide for Grants and Contracts. The NIDA Avant-Garde Award Program for HIV/AIDS Research supports individual scientists of exceptional creativity who propose high-impact research that will open new areas of HIV/AIDS research relevant to drug abuse and/or lead to new avenues for prevention and treatment of HIV/AIDS among drug abusers. The term avant-garde is used to describe highly innovative approaches that have the potential to be transformative. The proposed research should reflect approaches and ideas that are substantially different from those already being pursued by the investigator or others and should support the NIH HIV/AIDS Research Priorities https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-018.html. The NIDA Avant-Garde award supports innovative, basic research that may lead to improved preventive interventions or therapies; creative, new strategies to prevent disease transmission; novel approaches to improve disease outcomes; and creative approaches to eradicating HIV or improving the lives of those living with HIV.

Funding Opportunity PAR-23-113 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to provide support for institutional research training programs in Alzheimers Disease/Alzheimers Disease-Related Dementias (AD/ADRD). These institutional research training programs should produce well-trained neuroscientists who leave the program with the research skills and scientific knowledge to make a significant contribution to research on AD/ADRD cognitive impairment and dementia. Programs should be designed to enhance the breadth and depth of training across the spectrum AD/ADRD research areas (e.g. AD, Vascular Contributions to Cognitive Impairment and Dementia (VCID), Lewy Body Dementia (LBD), Fronto-temporal Dementia (FTD) and mixed dementias) by incorporating didactic, research and career development components within this theme into a program that fosters exceptional research skills and knowledge. Programs may support basic, clinical and/or translational research. Programs supported by this FOA must include formal components to ensure a thorough understanding of experimental design, statistical principles and methodological approaches, analytical skills, and skills for communicating science, both orally and in writing, to a wide variety of audiences. All programs are expected to design and/or provide opportunities and activities that will foster the development of quantitative literacy and the application of quantitative approaches to the trainees' research. These training programs are intended to be 2 years in duration and support training of one or more of the following groups: dissertation stage predoctoral students in their 3rd and/or 4th year of graduate school, postdoctoral fellows and fellowship-stage clinicians. (NINDS does not support first or second year graduate students under this FOA).